Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Radiation Oncology
•
Gastrointestinal Cancers
If colostomy is indicated prior to Nigro for locally advanced anal SCC, would you wait to simulate after this procedure or do you feel pelvic anatomy will not be distorted?
Answer from: Radiation Oncologist at Academic Institution
No reason to wait.
Sign In
or
Register
to read more
7052
Related Questions
Given the results of PLATO anal cancer study, is 4140 cGy the new standard for early stage anal cancer?
Is there increased risk from RT in patients with FAP (familial adenomatous polyposis)?
When treating with SBRT and immunotherapy for unresectable HCC, how do you sequence the treatment?
What if any, is your radiation approach to treating hepatic metastases abutting/invading luminal GI structures?
In a patient with pancreatic cancer who is heterozygous for the ATM c.875C>T (Pro292Leu) mutation with functional impairment in the gene product, is there any data or recommendation to support using SBRT vs. chemo-RT?
In a patient with esophageal cancer with lymph node involvement, would you consider treating with definitive chemo-radiation if they have a single area of retroperitoneal metastasis?
How would you treat a painful peripancreatic schwannoma in the setting of prior SBRT course?
When proceeding with neoadjuvant CRT, what is your radiotherapy plan in a patient with distal esophageal adenocarcinoma and an avid AP window lymph node?
In a patient with borderline resectable pancreatic adenocarcinoma s/p 10 cycles FOLFOX and aborted Whipple due to locally advanced disease, do you recommend dose escalation beyond 54 Gy?
For a patient with metastatic, poorly differentiated esophageal adenocarcinoma with an excellent systemic response to chemotherapy for 1 year, who now presents with isolated local progression and no new distant disease, would you consider treating the primary site with a higher palliative dose for more durable control?